WO2021151005A9 - Inhaled das181 to treat cancer in the lung - Google Patents

Inhaled das181 to treat cancer in the lung Download PDF

Info

Publication number
WO2021151005A9
WO2021151005A9 PCT/US2021/014772 US2021014772W WO2021151005A9 WO 2021151005 A9 WO2021151005 A9 WO 2021151005A9 US 2021014772 W US2021014772 W US 2021014772W WO 2021151005 A9 WO2021151005 A9 WO 2021151005A9
Authority
WO
WIPO (PCT)
Prior art keywords
das181
inhaled
lung
treat cancer
formulation containing
Prior art date
Application number
PCT/US2021/014772
Other languages
French (fr)
Other versions
WO2021151005A1 (en
Inventor
Jennifer Ho
Nancy Chang
Jianying Dong
Original Assignee
Ansun Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma, Inc. filed Critical Ansun Biopharma, Inc.
Publication of WO2021151005A1 publication Critical patent/WO2021151005A1/en
Publication of WO2021151005A9 publication Critical patent/WO2021151005A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are methods of treating lung cancer by administering a therapeutically effective amount of a polypeptide having sialidase activity, e.g., DAS181, topically to the lungs, wherein the method of administration includes inhalation of a dry powder formulation containing, e,g,. DAS181 with a metered dose inhaler and/or inhalation of a liquid nebulized formulation containing, e.g., DAS181 with a nebulizer.
PCT/US2021/014772 2020-01-22 2021-01-22 Inhaled das181 to treat cancer in the lung WO2021151005A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062964622P 2020-01-22 2020-01-22
US202062964593P 2020-01-22 2020-01-22
US62/964,622 2020-01-22
US62/964,593 2020-01-22

Publications (2)

Publication Number Publication Date
WO2021151005A1 WO2021151005A1 (en) 2021-07-29
WO2021151005A9 true WO2021151005A9 (en) 2022-01-13

Family

ID=76992652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/014772 WO2021151005A1 (en) 2020-01-22 2021-01-22 Inhaled das181 to treat cancer in the lung

Country Status (1)

Country Link
WO (1) WO2021151005A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102180849B1 (en) * 2006-01-24 2020-11-20 안선 바이오파르마, 아이엔씨. Technology for preparation of macromolecular microspheres
JP6810687B2 (en) * 2014-10-08 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Combination therapy with FAP and DR5-specific bispecific antibodies and chemotherapeutic agents

Also Published As

Publication number Publication date
WO2021151005A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
NZ548225A (en) Inhalant formulation containing sulfoakyl ether cyclodextrin and corticosteroid
Harb et al. Performance of large spacer versus nebulizer T-piece in single-limb noninvasive ventilation
Dhand Inhalation therapy in invasive and noninvasive mechanical ventilation
JP2015508780A5 (en)
Harb et al. Is Combihaler usable for aerosol delivery in single limb non-invasive mechanical ventilation?
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
Manthous et al. Treatment of bronchospasm by metered-dose inhaler albuterol in mechanically ventilated patients
NZ585857A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
MX2022009643A (en) Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation.
MX2021012723A (en) Positive pressure inhaler for delivery of inhalable medication and methods for use.
RU2008135580A (en) ALPHA-1-ANTITRIPSIN FOR TREATMENT OF EPISODES OF INFLAMMATION OF LUNG DISEASES
Coates et al. A comparison of the availability of tobramycin for inhalation from vented vs unvented nebulizers
WO2008005692A3 (en) INHALANT FORMULATION CONTAINING SULFOALKYL ETHER γ-CYCLODEXTRIN AND CORTICOSTEROID
BR0011343A (en) Drug delivery device, and, methods of administering a drug by inhalation, and of treating a patient with a respiratory disorder
KR20010020346A (en) Method of delivering halotherapy
WO2012040228A3 (en) Aerosol composition for administering drugs
EA202091199A1 (en) DRUG FOR THE PREVENTION OR TREATMENT OF RHINOVIRAL INFECTION
Alhamad et al. Effect of aerosol devices and administration techniques on drug delivery in a simulated spontaneously breathing pediatric tracheostomy model
TW200602054A (en) Use of compounds in a dry powder inhaler
WO2021151005A9 (en) Inhaled das181 to treat cancer in the lung
JP2014523909A (en) Formulation and method and system of amikacin and fosfomycin combination for the treatment of ventilator-associated pneumonia (VAP) and ventilator-associated trachea (VAT) bronchitis
MX2020010977A (en) Methods of treating fungal infections.
SE0303091D0 (en) Combined doses of tiotropium andfluticasone
Souëf The meaning of lung dose
Boules et al. Effect of pressures and type of ventilation on aerosol delivery to chronic obstructive pulmonary disease patients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21744409

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21744409

Country of ref document: EP

Kind code of ref document: A1